Return to homepagePandemic Pact

Therapeutic repositioning aimed at inhibition of ACE2 expression and proteolysis of viral S trimer

  • Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Total publications:0 publications

Grant number: COV20_00047

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)

  • Principal Investigator

    Manuel Portero-Otin

  • Research Location

    Spain

  • Lead Research Institution

    INSTITUTO INV. BIOMEDICA DE LLEIDA. FUNDACION DR. PIFARRE (IRBLLEIDA)

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Several cell lines (eg Vero or Calu-3) express in their cell membrane the protein ACE2, which participates in the union with the S trimer of SARS-Cov-2, and also presents proteolytic activities for the activation of the same protein, two of the hypothetical requirements for entry of the virus into the human host. According to her, those substances that can decrease the role of ACE2 or the activity of host proteases on protein S, could be used for the treatment of infarction. Thus, i) commercial drug libraries authorized for use in humans and ii) antisense oligonucleotides with peptide vahicles will be used as molecules as a new therapeutic approach.